Elpiscience Announces First Patient Dosed in Phase I/II Clinical Study of ES104 for Treatment of Colorectal Cancer

Elpiscience Biopharmaceuticals, Inc. announced that the first patient has been dosed in a Phase I/II clinical study, evaluating the safety, tolerability, preliminary anti-tumor efficacy and pharmacokinetics of ES104, a bispecific antibody that simultaneously blocks the DLL4 and VEGF-A signaling pathways that are critical to angiogenesis and tumor vascularization.